<DOC>
	<DOCNO>NCT00267592</DOCNO>
	<brief_summary>The purpose study estimate overall survival adult patient newly diagnose glioblastoma multiforme treat talampanel radiation therapy concurrent adjuvant temozolomide . This study also determine toxicity toxicity rate talampanel therapeutic regimen .</brief_summary>
	<brief_title>Safety Efficacy Talampanel Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must 18 year age Patients must histologically confirm supratentorial Grade IV astrocytoma ( glioblastoma multiforme ) Patients must prior radiation therapy , chemotherapy ( include Gliadel wafer ) , immunotherapy therapy biologic agent , hormonal therapy . Glucocorticoid therapy allow . Patients must recover immediate postoperative period maintain stable corticosteroid regimen ( increase 5 day ) prior start treatment . Patients must Karnofsky performance least 60 % . Patients serious concurrent infection medical illness . Patients receive concurrent chemotherapeutics investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>